NDAINJECTIONINJECTABLE
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 29m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTIVA (remifentanil hydrochloride) is a potent synthetic opioid agonist administered intravenously for anesthesia and analgesia. It is used perioperatively for induction and maintenance of general anesthesia, as well as for sedation and analgesia in mechanically ventilated patients in critical care settings. Remifentanil has a rapid onset and offset due to ester metabolism, making it suitable for short procedures and continuous infusions.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating potential team consolidation and shift toward lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Mindfulness-Based Intervention to Reduce Stress Through the Cultivation of Loving-Kindness, Compassion, Joy, and Equanimity in Healthcare Professionals
Started Oct 2025
80 enrolled
Stress (Psychology)InflamationPsychosocial Functioning
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
Started Nov 2022
1,800 enrolled
Streptococcus Pneumoniae Infection
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
Started Aug 2022
306 enrolled
Group B Streptococcus Infections
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Started Aug 2021
56 enrolled
Cancer of the Head and Neck
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
Started Mar 2019
20 enrolled
Peanut Allergy
Worked on ULTIVA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.